JAK1 and atopic eczema: This finding is consistent with recent clinical trials and meta-analyses comparing the efficacy of various targeted systemic therapies in patients with atopic dermatitis, which identified JAK1-selective inhibitors as the most effective agents for alleviating pruritus compared with biologics and other types of JAK inhibitors.